12:00 AM
 | 
Aug 08, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

RoActemra regulatory update

The European Commission approved an extended indication for Roche's RoActemra tocilizumab to include the treatment of systemic juvenile idiopathic arthritis in patients >=2 years old who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids....

Read the full 164 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >